Avalo Therapeutics vs iBio
Avalo Therapeutics reported revenue of $0 million in fiscal 2025, about the same as iBio's $0 million in fiscal 2026. Avalo Therapeutics' revenue fell 86.6% in its latest year, and iBio's fell 75.0%. Avalo Therapeutics had an operating margin of -123601.7%, against -35141.0% at iBio. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Avalo Therapeutics | iBio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $0M | $0M |
| Revenue growth | −86.6% | −75.0% |
| Revenue growth a year, last 5 years | −56.9% | −47.0% |
| Gross margin | — | — |
| Operating margin | −123,601.7% | −35,141.0% |
| Net margin | −132,642.4% | −33,044.0% |
| Free cash flow | — | −$24M |
| Free cash flow margin | — | −23,796.0% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 78.8% | 891.1% |
| Last close | $6.75 | $0.80 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $8.3 million | bought $98,110, sold $0 |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Avalo TherapeuticsiBio
Operating margin
Percent of revenue
Avalo TherapeuticsiBio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Avalo TherapeuticsiBio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Avalo Therapeutics and iBio pages.